BerGenBio: Developing first-in-class AXL inhibitors for aggressive diseases, including advanced, treatment resistant cancers

Alison Messom
Director of Clinical Operations
Debbie Molyneux
Interim HR Director
Endre Kjærland
Associate Director of IP and Contracts
Gro Gausdal
Director of Research & Bergen Site Leader
Hani Gabra
Chief Medical Officer
James Barnes
Director of Operations
Rune Skeie
Chief Financial Officer

No teams yet!

No jobs yet!

No wires yet!

By clicking "Continue" or continuing to use our site, you acknowledge that you accept our Privacy Policy and Terms of Use. We also use cookies to provide you with the best possible experience on our website.